FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia
Prognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We ret...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000840 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113929297002496 |
|---|---|
| author | Donghyun Kim Grerk Sutamtewagul Yeonhwa Yu |
| author_facet | Donghyun Kim Grerk Sutamtewagul Yeonhwa Yu |
| author_sort | Donghyun Kim |
| collection | DOAJ |
| description | Prognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We retrospectively explored two publicly available AML RNA-Seq datasets and found that inferior overall survival was associated with high-FLT3 and low-NPM1 transcript levels (“FLT3high/NPM1low”) compared to low-FLT3 and high-NPM1 transcript levels (“FLT3low/NPM1high”) in adult de novo AML patients, with a hazard ratio for death of at least 2. Transcript level-dependent differential overall survival was independent from the underlying FLT3 or NPM1 genotypes. Our two-gene RNA expression-based de novo AML risk stratification may supplement and fine-tune traditional genetic aberration-based prognostication methods. |
| format | Article |
| id | doaj-art-2ce54ff26c3f4fe4aa1d8790ccafb723 |
| institution | OA Journals |
| issn | 2213-0489 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-2ce54ff26c3f4fe4aa1d8790ccafb7232025-08-20T02:37:02ZengElsevierLeukemia Research Reports2213-04892025-01-012310049410.1016/j.lrr.2024.100494FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid LeukemiaDonghyun Kim0Grerk Sutamtewagul1Yeonhwa Yu2Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, United States; Correspondence author at: 200 Hawkins Dr., C316 GH, Iowa City, IA 52242, United States.Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, United StatesIndependent Researcher, Gimpo-si, Gyeonggi-do 10090, South KoreaPrognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We retrospectively explored two publicly available AML RNA-Seq datasets and found that inferior overall survival was associated with high-FLT3 and low-NPM1 transcript levels (“FLT3high/NPM1low”) compared to low-FLT3 and high-NPM1 transcript levels (“FLT3low/NPM1high”) in adult de novo AML patients, with a hazard ratio for death of at least 2. Transcript level-dependent differential overall survival was independent from the underlying FLT3 or NPM1 genotypes. Our two-gene RNA expression-based de novo AML risk stratification may supplement and fine-tune traditional genetic aberration-based prognostication methods.http://www.sciencedirect.com/science/article/pii/S2213048924000840Acute myeloid leukemiaGene expressionPrognostic biomarkerFLT3NPM1 |
| spellingShingle | Donghyun Kim Grerk Sutamtewagul Yeonhwa Yu FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia Leukemia Research Reports Acute myeloid leukemia Gene expression Prognostic biomarker FLT3 NPM1 |
| title | FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia |
| title_full | FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia |
| title_fullStr | FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia |
| title_full_unstemmed | FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia |
| title_short | FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute Myeloid Leukemia |
| title_sort | flt3 and npm1 mrna expression based risk stratification of de novo acute myeloid leukemia |
| topic | Acute myeloid leukemia Gene expression Prognostic biomarker FLT3 NPM1 |
| url | http://www.sciencedirect.com/science/article/pii/S2213048924000840 |
| work_keys_str_mv | AT donghyunkim flt3andnpm1mrnaexpressionbasedriskstratificationofdenovoacutemyeloidleukemia AT grerksutamtewagul flt3andnpm1mrnaexpressionbasedriskstratificationofdenovoacutemyeloidleukemia AT yeonhwayu flt3andnpm1mrnaexpressionbasedriskstratificationofdenovoacutemyeloidleukemia |